Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015; 7(16): 2009-2019 [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009]
Corresponding Author of This Article
Antonio Facciorusso, MD, Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale L.Pinto, 1, 71100 Foggia, Italy. antonio.facciorusso@virgilio.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Aug 8, 2015; 7(16): 2009-2019 Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.2009
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
Antonio Facciorusso, Raffaele Licinio, Nicola Muscatiello, Alfredo Di Leo, Michele Barone
Antonio Facciorusso, Nicola Muscatiello, Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, Italy
Raffaele Licinio, Alfredo Di Leo, Michele Barone, Gastroenterology Unit, Department of Emergency and Organ Transplantation, University of Bari, 70126 Bari, Italy
Author contributions: Licinio R and Muscatiello N performed the bibliographic research; Facciorusso A wrote the paper; Di Leo A and Barone M revised the manuscript; all the authors contributed to the article.
Conflict-of-interest statement: None of the authors has conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Antonio Facciorusso, MD, Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale L.Pinto, 1, 71100 Foggia, Italy. antonio.facciorusso@virgilio.it
Telephone: +39-08-81732154 Fax: +39-08-81732135
Received: April 18, 2015 Peer-review started: April 19, 2015 First decision: June 25, 2015 Revised: June 26, 2015 Accepted: July 23, 2015 Article in press: July 27, 2015 Published online: August 8, 2015 Processing time: 112 Days and 10.2 Hours
Core Tip
Core tip: Transarterial chemoembolization (TACE) represents the standard of care for patients with large or multinodular hepatocellular carcinoma (HCC). However, TACE is a heterogeneous technique varying in terms of chemotherapeutic agents, devices and schedule. In order to overcome these drawbacks of conventional TACE (cTACE), drug-eluting beads have been developed. Unfortunately, despite its theoretical advantages, definitive data in favor of its superiority over cTACE are still lacking. TACE represents the standard-of-care for intermediate-stage HCC, in competition with other therapeutic options (surgery and radioembolization). Other fields of application are the pre-transplant setting and the early stage (in patients unsuitable to curative therapy).
